Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Debt (2020 - 2022)

Mereo BioPharma (MREO) has disclosed Total Debt for 3 consecutive years, with $486000.0 as the latest value for Q4 2022.

  • Quarterly Total Debt fell 97.49% to $486000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $486000.0 through Dec 2022, down 97.49% year-over-year, with the annual reading at $19.4 million for FY2021, 9.03% down from the prior year.
  • Total Debt for Q4 2022 was $486000.0 at Mereo BioPharma, down from $19.4 million in the prior quarter.
  • The five-year high for Total Debt was $21.3 million in Q4 2020, with the low at $486000.0 in Q4 2022.
  • Average Total Debt over 3 years is $13.7 million, with a median of $19.4 million recorded in 2021.
  • The sharpest move saw Total Debt fell 9.03% in 2021, then plummeted 97.49% in 2022.
  • Over 3 years, Total Debt stood at $21.3 million in 2020, then decreased by 9.03% to $19.4 million in 2021, then tumbled by 97.49% to $486000.0 in 2022.
  • According to Business Quant data, Total Debt over the past three periods came in at $486000.0, $19.4 million, and $21.3 million for Q4 2022, Q4 2021, and Q4 2020 respectively.